Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 116

1.

Cost-effectiveness of Financial Incentives for Patients and Physicians to Manage Low-Density Lipoprotein Cholesterol Levels.

Pandya A, Asch DA, Volpp KG, Sy S, Troxel AB, Zhu J, Weinstein MC, Rosenthal MB, Gaziano TA.

JAMA Netw Open. 2018 Sep 7;1(5):e182008. doi: 10.1001/jamanetworkopen.2018.2008.

PMID:
30646152
2.

Cost-Effectiveness of a US National Sugar-Sweetened Beverage Tax With a Multistakeholder Approach: Who Pays and Who Benefits.

Wilde P, Huang Y, Sy S, Abrahams-Gessel S, Jardim TV, Paarlberg R, Mozaffarian D, Micha R, Gaziano T.

Am J Public Health. 2019 Feb;109(2):276-284. doi: 10.2105/AJPH.2018.304803. Epub 2018 Dec 20.

PMID:
30571305
3.

A model-based analysis of pharmacokinetic-pharmacodynamic (PK/PD) indices of avibactam against Pseudomonas aeruginosa.

Sy SKB, Zhuang L, Xia H, Schuck VJ, Nichols WW, Derendorf H.

Clin Microbiol Infect. 2018 Oct 28. pii: S1198-743X(18)30717-1. doi: 10.1016/j.cmi.2018.10.014. [Epub ahead of print]

PMID:
30394361
4.

Dose Optimization of Moxifloxacin and Linezolid Against Tuberculosis Using Mathematical Modeling and Simulation.

Heinrichs MT, Drusano GL, Brown DL, Maynard MS, Sy SKB, Rand KH, Peloquin CA, Louie A, Derendorf H.

Int J Antimicrob Agents. 2018 Oct 29. pii: S0924-8579(18)30304-2. doi: 10.1016/j.ijantimicag.2018.10.012. [Epub ahead of print]

PMID:
30385322
5.

Cost-effectiveness of financial incentives and disincentives for improving food purchases and health through the US Supplemental Nutrition Assistance Program (SNAP): A microsimulation study.

Mozaffarian D, Liu J, Sy S, Huang Y, Rehm C, Lee Y, Wilde P, Abrahams-Gessel S, de Souza Veiga Jardim T, Gaziano T, Micha R.

PLoS Med. 2018 Oct 2;15(10):e1002661. doi: 10.1371/journal.pmed.1002661. eCollection 2018 Oct.

6.

Screening for Cervical Cancer in Primary Care: A Decision Analysis for the U.S. Preventive Services Task Force [Internet].

Kim JJ, Burger EA, Regan C, Sy S.

Rockville, MD: Agency for Healthcare Research and Quality (US); 2018 Aug. No abstract available.

PMID:
30212064
Free Books & Documents
7.

Screening for Cervical Cancer in Primary Care: A Decision Analysis for the US Preventive Services Task Force.

Kim JJ, Burger EA, Regan C, Sy S.

JAMA. 2018 Aug 21;320(7):706-714. doi: 10.1001/jama.2017.19872.

PMID:
30140882
8.

Health impact of delayed implementation of cervical cancer screening programs in India: A modeling analysis.

Campos NG, Tsu V, Jeronimo J, Regan C, Resch S, Clark A, Sy S, Kim JJ.

Int J Cancer. 2019 Feb 15;144(4):687-696. doi: 10.1002/ijc.31823. Epub 2018 Oct 16.

PMID:
30132850
9.

Clinical Pharmacokinetics and Pharmacodynamics of Ceftazidime-Avibactam Combination: A Model-Informed Strategy for its Clinical Development.

Sy SKB, Zhuang L, Sy S, Derendorf H.

Clin Pharmacokinet. 2018 Aug 11. doi: 10.1007/s40262-018-0705-y. [Epub ahead of print] Review.

PMID:
30097887
10.

Cost-Effectiveness of Cervical Cancer Screening in Women Living With HIV in South Africa: A Mathematical Modeling Study.

Campos NG, Lince-Deroche N, Chibwesha CJ, Firnhaber C, Smith JS, Michelow P, Meyer-Rath G, Jamieson L, Jordaan S, Sharma M, Regan C, Sy S, Liu G, Tsu V, Jeronimo J, Kim JJ.

J Acquir Immune Defic Syndr. 2018 Oct 1;79(2):195-205. doi: 10.1097/QAI.0000000000001778.

11.

Community-based HPV self-collection versus visual inspection with acetic acid in Uganda: a cost-effectiveness analysis of the ASPIRE trial.

Mezei AK, Pedersen HN, Sy S, Regan C, Mitchell-Foster SM, Byamugisha J, Sekikubo M, Armstrong H, Rawat A, Singer J, Ogilvie GS, Kim JJ, Campos NG.

BMJ Open. 2018 Jun 12;8(6):e020484. doi: 10.1136/bmjopen-2017-020484.

12.

Health and economic benefits of single-dose HPV vaccination in a Gavi-eligible country.

Burger EA, Campos NG, Sy S, Regan C, Kim JJ.

Vaccine. 2018 Aug 6;36(32 Pt A):4823-4829. doi: 10.1016/j.vaccine.2018.04.061. Epub 2018 May 26.

13.

Development and Calibration of a Mathematical Model of Anal Carcinogenesis for High-Risk HIV-Infected Men.

Burger EA, Dyer MA, Sy S, Palefsky JM, de Pokomandy A, Coutlee F, Silverberg MJ, Kim JJ.

J Acquir Immune Defic Syndr. 2018 Sep 1;79(1):10-19. doi: 10.1097/QAI.0000000000001727.

PMID:
29757775
14.

Change in Topoisomerase 1-Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol.

Rugo HS, Cortes J, Awada A, O'Shaughnessy J, Twelves C, Im SA, Hannah A, Lu L, Sy S, Caygill K, Zajchowski DA, Davis DW, Tagliaferri M, Hoch U, Perez EA.

Clin Cancer Res. 2018 Jul 15;24(14):3348-3357. doi: 10.1158/1078-0432.CCR-17-3059. Epub 2018 Apr 4.

PMID:
29618616
15.

Integrated population pharmacokinetics of etirinotecan pegol and its four metabolites in cancer patients with solid tumors.

Sy SKB, Chia YL, Gordi T, Hoch U, Eldon MA.

Cancer Chemother Pharmacol. 2018 May;81(5):897-909. doi: 10.1007/s00280-018-3562-3. Epub 2018 Mar 21.

16.

Inefficiencies of over-screening and under-screening for cervical cancer prevention in the U.S.

Castle PE, Wheeler CM, Campos NG, Sy S, Burger EA, Kim JJ; New Mexico HPV Pap Registry Steering Committee.

Prev Med. 2018 Jun;111:177-179. doi: 10.1016/j.ypmed.2018.03.011. Epub 2018 Mar 14.

PMID:
29548787
17.

Application of Pharmacometric Analysis in the Design of Clinical Pharmacology Studies for Biosimilar Development.

Zhu P, Sy SKB, Skerjanec A.

AAPS J. 2018 Mar 7;20(2):40. doi: 10.1208/s12248-018-0196-7.

PMID:
29516330
18.

A mathematical model-based analysis of the time-kill kinetics of ceftazidime/avibactam against Pseudomonas aeruginosa.

Sy SKB, Zhuang L, Xia H, Beaudoin ME, Schuck VJ, Nichols WW, Derendorf H.

J Antimicrob Chemother. 2018 May 1;73(5):1295-1304. doi: 10.1093/jac/dkx537.

PMID:
29415212
19.

Effect of Time to Diagnostic Testing for Breast, Cervical, and Colorectal Cancer Screening Abnormalities on Screening Efficacy: A Modeling Study.

Rutter CM, Kim JJ, Meester RGS, Sprague BL, Burger EA, Zauber AG, Ergun MA, Campos NG, Doubeni CA, Trentham-Dietz A, Sy S, Alagoz O, Stout N, Lansdorp-Vogelaar I, Corley DA, Tosteson ANA.

Cancer Epidemiol Biomarkers Prev. 2018 Feb;27(2):158-164. doi: 10.1158/1055-9965.EPI-17-0378. Epub 2017 Nov 17.

PMID:
29150480
20.

Fixed-dose combinations: a potential means to boost drug development for selected drugs.

Oo C, Sy SKB.

Drug Discov Today. 2018 Mar;23(3):457-459. doi: 10.1016/j.drudis.2017.11.001. Epub 2017 Nov 14. No abstract available.

PMID:
29146518
21.

Dermal pharmacokinetics of pyrazinamide determined by microdialysis sampling in rats.

Voelkner NMF, Voelkner A, Costa J, Sy SKB, Hermes J, Weitzel J, Morales S, Derendorf H.

Int J Antimicrob Agents. 2018 Feb;51(2):190-196. doi: 10.1016/j.ijantimicag.2017.10.001. Epub 2017 Oct 13.

PMID:
29032112
22.

Choosing wisely: a model-based analysis evaluating the trade-offs in cancer benefit and diagnostic referrals among alternative HPV testing strategies in Norway.

Burger EA, Pedersen K, Sy S, Kristiansen IS, Kim JJ.

Br J Cancer. 2017 Sep 5;117(6):783-790. doi: 10.1038/bjc.2017.248. Epub 2017 Aug 3.

23.

Experimental design and modelling approach to evaluate efficacy of β-lactam/β-lactamase inhibitor combinations.

Sy SKB, Derendorf H.

Clin Microbiol Infect. 2018 Jul;24(7):707-715. doi: 10.1016/j.cmi.2017.07.020. Epub 2017 Jul 29.

PMID:
28760708
24.

Sevelamer resin bezoar presenting as a cecal mass.

Sy S, Siddiki H, Horsley-Silva J, Byrne T, Lam-Himlin D.

Gastrointest Endosc. 2017 Dec;86(6):1186-1187. doi: 10.1016/j.gie.2017.06.021. Epub 2017 Jul 1. No abstract available.

PMID:
28673643
25.

Pharmacodynamic Evaluation of Fosfomycin against Escherichia coli and Klebsiella spp. from Urinary Tract Infections and the Influence of pH on Fosfomycin Activities.

Fedrigo NH, Mazucheli J, Albiero J, Shinohara DR, Lodi FG, Machado ACDS, Sy SKB, Tognim MCB.

Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e02498-16. doi: 10.1128/AAC.02498-16. Print 2017 Aug.

26.
27.

Validation of a Cardiovascular Disease Policy Microsimulation Model Using Both Survival and Receiver Operating Characteristic Curves.

Pandya A, Sy S, Cho S, Alam S, Weinstein MC, Gaziano TA.

Med Decis Making. 2017 Oct;37(7):802-814. doi: 10.1177/0272989X17706081. Epub 2017 May 10.

28.

A retrospective review of the dermatologic manifestations of chronic arsenic poisoning in the Philippines.

Sy SMT, Salud-Gnilo CM, Yap-Silva C, Tababa EJL.

Int J Dermatol. 2017 Jul;56(7):721-725. doi: 10.1111/ijd.13615. Epub 2017 Mar 28.

PMID:
28349520
29.

Respiratory viruses in patients with influenza-like illness in Senegal: Focus on human respiratory adenoviruses.

Niang MN, Diop NS, Fall A, Kiori DE, Sarr FD, Sy S, Goudiaby D, Barry MA, Fall M, Dia N.

PLoS One. 2017 Mar 22;12(3):e0174287. doi: 10.1371/journal.pone.0174287. eCollection 2017.

30.

Modeling Ovarian Cancer Multicellular Spheroid Behavior in a Dynamic 3D Peritoneal Microdevice.

Li SS, Ip CK, Tang MY, Sy SK, Yung S, Chan TM, Yang M, Shum HC, Wong AS.

J Vis Exp. 2017 Feb 18;(120). doi: 10.3791/55337.

PMID:
28287578
31.

Prediction of in vivo and in vitro infection model results using a semimechanistic model of avibactam and aztreonam combination against multidrug resistant organisms.

Sy S, Zhuang L, Xia H, Beaudoin ME, Schuck VJ, Derendorf H.

CPT Pharmacometrics Syst Pharmacol. 2017 Mar;6(3):197-207. doi: 10.1002/psp4.12159. Epub 2017 Feb 1.

32.

Potentiation of ceftazidime by avibactam against β-lactam-resistant Pseudomonas aeruginosa in an in vitro infection model.

Sy SK, Zhuang L, Beaudoin ME, Kircher P, Tabosa MA, Cavalcanti NC, Grunwitz C, Pieper S, Schuck VJ, Nichols WW, Derendorf H.

J Antimicrob Chemother. 2017 Apr 1;72(4):1109-1117. doi: 10.1093/jac/dkw535.

PMID:
28077672
33.

Ultrafast time-stretch imaging at 932 nm through a new highly-dispersive fiber.

Wei X, Kong C, Sy S, Ko H, Tsia KK, Wong KK.

Biomed Opt Express. 2016 Nov 18;7(12):5208-5217. doi: 10.1364/BOE.7.005208. eCollection 2016 Dec 1.

34.

Etirinotecan pegol administration is associated with lower incidences of neutropenia compared to irinotecan administration.

Sy SK, Sweeney TD, Ji C, Hoch U, Eldon MA.

Cancer Chemother Pharmacol. 2017 Jan;79(1):57-67. doi: 10.1007/s00280-016-3192-6. Epub 2016 Nov 30.

35.
36.

Cost-effective management of women with minor cervical lesions: Revisiting the application of HPV DNA testing.

Pedersen K, Burger EA, Sy S, Kristiansen IS, Kim JJ.

Gynecol Oncol. 2016 Nov;143(2):326-333. doi: 10.1016/j.ygyno.2016.08.231. Epub 2016 Aug 17.

37.

Optimal Cervical Cancer Screening in Women Vaccinated Against Human Papillomavirus.

Kim JJ, Burger EA, Sy S, Campos NG.

J Natl Cancer Inst. 2016 Oct 18;109(2). pii: djw216. Print 2017 Feb.

38.

The Cost-Effectiveness of Cervical Self-Sampling to Improve Routine Cervical Cancer Screening: The Importance of Respondent Screening History and Compliance.

Burger EA, Sy S, Nygård M, Kim JJ.

Cancer Epidemiol Biomarkers Prev. 2017 Jan;26(1):95-103. doi: 10.1158/1055-9965.EPI-16-0350. Epub 2016 Sep 13.

39.

Molecular Functionalization of Graphene Oxide for Next-Generation Wearable Electronics.

Zarrin H, Sy S, Fu J, Jiang G, Kang K, Jun YS, Yu A, Fowler M, Chen Z.

ACS Appl Mater Interfaces. 2016 Sep 28;8(38):25428-37. doi: 10.1021/acsami.6b06769. Epub 2016 Sep 15.

PMID:
27580066
40.

Population Pharmacokinetic and Covariate Analysis of Apatinib, an Oral Tyrosine Kinase Inhibitor, in Healthy Volunteers and Patients with Solid Tumors.

Yu M, Gao Z, Dai X, Gong H, Zhang L, Chen X, Zhong DF, Sy SK.

Clin Pharmacokinet. 2017 Jan;56(1):65-76. doi: 10.1007/s40262-016-0427-y.

PMID:
27379402
41.

Epidemiology and Molecular Characterization of Human Respiratory Syncytial Virus in Senegal after Four Consecutive Years of Surveillance, 2012-2015.

Fall A, Dia N, Cisse el HA, Kiori DE, Sarr FD, Sy S, Goudiaby D, Richard V, Niang MN.

PLoS One. 2016 Jun 17;11(6):e0157163. doi: 10.1371/journal.pone.0157163. eCollection 2016.

42.

Enteroviruses and Rhinoviruses: Molecular Epidemiology of the Most Influenza-Like Illness Associated Viruses in Senegal.

Fall A, Dia N, Kébé O, Sarr FD, Kiori DE, Cissé el HA, Sy S, Goudiaby D, Richard V, Diop OM, Niang MN.

Am J Trop Med Hyg. 2016 Aug 3;95(2):339-47. doi: 10.4269/ajtmh.15-0799. Epub 2016 May 31.

43.

Stemness and chemoresistance in epithelial ovarian carcinoma cells under shear stress.

Ip CK, Li SS, Tang MY, Sy SK, Ren Y, Shum HC, Wong AS.

Sci Rep. 2016 Jun 1;6:26788. doi: 10.1038/srep26788.

44.

Pharmacodynamic Evaluation of the Potential Clinical Utility of Fosfomycin and Meropenem in Combination Therapy against KPC-2-Producing Klebsiella pneumoniae.

Albiero J, Sy SK, Mazucheli J, Caparroz-Assef SM, Costa BB, Alves JL, Gales AC, Tognim MC.

Antimicrob Agents Chemother. 2016 Jun 20;60(7):4128-39. doi: 10.1128/AAC.03099-15. Print 2016 Jul.

45.

Quantitation of the impact of CYP3A5 A6986G polymorphism on quetiapine pharmacokinetics by simulation of target attainment.

Shilbayeh SA, Sy SK, Melhem M, Zmeili R, Derendorf H.

Clin Pharmacol Drug Dev. 2015 Sep;4(5):387-94. doi: 10.1002/cpdd.172. Epub 2015 Jan 12.

PMID:
27137148
46.

In vitro pharmacokinetics/pharmacodynamics of the combination of avibactam and aztreonam against MDR organisms.

Sy SK, Beaudoin ME, Zhuang L, Löblein KI, Lux C, Kissel M, Tremmel R, Frank C, Strasser S, Heuberger JA, Mulder MB, Schuck VJ, Derendorf H.

J Antimicrob Chemother. 2016 Jul;71(7):1866-80. doi: 10.1093/jac/dkw082. Epub 2016 Apr 21.

PMID:
27107096
47.

Gentamicin dosing strategy in patients with end-stage renal disease receiving haemodialysis: evaluation using a semi-mechanistic pharmacokinetic/pharmacodynamic model.

Zhuang L, He Y, Xia H, Liu Y, Sy SK, Derendorf H.

J Antimicrob Chemother. 2016 Apr;71(4):1012-21. doi: 10.1093/jac/dkv428. Epub 2015 Dec 24.

PMID:
26702923
48.

Pharmacokinetics and pharmacodynamics in antibiotic dose optimization.

Sy SK, Zhuang L, Derendorf H.

Expert Opin Drug Metab Toxicol. 2016;12(1):93-114. doi: 10.1517/17425255.2016.1123250. Epub 2015 Dec 14. Review.

PMID:
26652832
49.

Rapid and efficient method for the quantification of lychnopholide in rat plasma by liquid chromatography-tandem mass spectrometry for pharmacokinetic application.

Lachi-Silva L, Sousa JPB, Montanha MC, Sy SKB, Lopes JLC, Silva DB, Lopes NP, Diniz A, Kimura E.

Biomed Chromatogr. 2016 Jul;30(7):1092-1096. doi: 10.1002/bmc.3654. Epub 2016 Jan 3.

PMID:
26577838
50.

Cost-Effectiveness of Screening for Primary Aldosteronism and Subtype Diagnosis in the Resistant Hypertensive Patients.

Lubitz CC, Economopoulos KP, Sy S, Johanson C, Kunzel HE, Reincke M, Gazelle GS, Weinstein MC, Gaziano TA.

Circ Cardiovasc Qual Outcomes. 2015 Nov;8(6):621-30. doi: 10.1161/CIRCOUTCOMES.115.002002. Epub 2015 Nov 10.

Supplemental Content

Support Center